Bourgeon Capital Management LLC bought a new position in shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 20,000 shares of the biopharmaceutical company’s stock, valued at approximately $72,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Achillion Pharmaceuticals by 142.5% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,227 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 4,247 shares during the last quarter. Virtus ETF Advisers LLC grew its stake in shares of Achillion Pharmaceuticals by 10.0% during the second quarter. Virtus ETF Advisers LLC now owns 95,598 shares of the biopharmaceutical company’s stock worth $256,000 after buying an additional 8,694 shares during the last quarter. Bank of Montreal Can bought a new stake in shares of Achillion Pharmaceuticals during the second quarter worth $30,000. Bank of New York Mellon Corp grew its stake in shares of Achillion Pharmaceuticals by 2.3% during the second quarter. Bank of New York Mellon Corp now owns 650,592 shares of the biopharmaceutical company’s stock worth $1,744,000 after buying an additional 14,757 shares during the last quarter. Finally, Meeder Asset Management Inc. grew its stake in shares of Achillion Pharmaceuticals by 677.1% during the third quarter. Meeder Asset Management Inc. now owns 19,551 shares of the biopharmaceutical company’s stock worth $70,000 after buying an additional 17,035 shares during the last quarter. 78.77% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Achillion Pharmaceuticals stock traded up $0.01 during trading on Friday, hitting $6.36. The company’s stock had a trading volume of 1,598,800 shares, compared to its average volume of 2,042,478. Achillion Pharmaceuticals, Inc. has a 52 week low of $1.29 and a 52 week high of $6.46. The stock has a market cap of $888.45 million, a price-to-earnings ratio of -12.47 and a beta of 1.67. The stock has a 50-day moving average price of $4.88 and a two-hundred day moving average price of $3.78.

Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.02. Analysts predict that Achillion Pharmaceuticals, Inc. will post -0.59 EPS for the current fiscal year.

In related news, CEO Joseph Truitt sold 133,484 shares of the business’s stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $6.37, for a total value of $850,293.08. Following the sale, the chief executive officer now owns 103,734 shares of the company’s stock, valued at $660,785.58. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 4.58% of the company’s stock.

ACHN has been the topic of a number of research reports. Leerink Swann cut shares of Achillion Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $6.30 target price on the stock. in a research note on Friday, October 18th. ValuEngine raised shares of Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, October 16th. Svb Leerink cut shares of Achillion Pharmaceuticals from an “outperform” rating to a “market perform” rating and boosted their target price for the stock from $5.00 to $6.30 in a research note on Friday, October 18th. JMP Securities cut shares of Achillion Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday. Finally, BidaskClub cut shares of Achillion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 12th. Three equities research analysts have rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $4.96.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis.

Featured Story: What is the price-sales ratio?

Want to see what other hedge funds are holding ACHN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN).

Institutional Ownership by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.